| Code | CSB-RA023981MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ABBV-368, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor delivers signals that enhance T cell-mediated immune responses and promote immunological memory. TNFRSF4 has emerged as an important therapeutic target in immuno-oncology, as its activation can enhance anti-tumor immunity by promoting T cell expansion and overcoming immunosuppressive mechanisms within the tumor microenvironment.
ABBV-368 represents an agonistic antibody designed to stimulate TNFRSF4 signaling and enhance anti-tumor immune responses, particularly in combination with other immunotherapies. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF4-mediated immune modulation, studying T cell biology, and exploring combination immunotherapy strategies in preclinical cancer models. It supports mechanistic studies of costimulatory pathways and therapeutic development in oncology research.
There are currently no reviews for this product.